Loading...

Omron India eyes USD40 mn by 2018/19

Image

27-Dec-15 Japanese health monitor maker Omron Healthcare is looking at more than doubling its revenues in India to USD40 mn by 2018/19, on the back of sales network expansion. The company, which is expecting sales of USD19 mn this year, is also open to the idea of opening a factory in India depending on the demand of its products. [image: Ormon Healthcare].

Read More

AstraZeneca investing USD800 mn to go local in China

Image

16-Dec-15 AstraZeneca aims to build up its already strong position in China by making and developing more medicines locally, and will invest more than USD800 mn in the country over the next 10 years. The British drugmaker's decision to step up investment, notably through a strategic alliance with WuXi AppTec, chimes with Beijing's desire to see more treatments made in China. [image: China Daily]

Read More

Indian regulators, medical device associations focus on new guidelines

Image

11-Dec-15 India’s Ministry of Health & Family Welfare (MOHFW) and the Central Drugs Standard Control Organization (CDSCO) have met with medical device association representatives to discuss how the country can become a hub for device manufacturing and begin to align with global regulations. The discussion centered on increasing device exports and evaluating new guidance for the industry. [image: RAPS]

Read More

Making healthcare accessible in Singapore

Image

11-Dec-15 Singapore will seek to improve healthcare accessibility for patients, and promote innovation in medical technology, the Minister for Trade and Industry has said. To boost healthcare accessibility, he said the healthcare workforce has to grow by 50% by 2020. Singapore will also add at least 1,700 acute beds and double the number of community hospital beds to 3,000. [image: APACMed]

Read More

China's reforms will hurt US manufacturers

Image

08-Dec-15 China's implementation of healthcare reforms, changing the approval process for new medical devices and favoring local manufacturers will restrain growth for US medical manufacturers, says Moody's. China's healthcare reforms will be particularly credit negative for companies that make complex devices, such as Medtronic, Boston Scientific and St Jude. [image: Shannon Stapleton / Reuters]

Read More
Share